TICKERNERD
Menu
BRVEHealthcare · Biotechnology

BRVE Stock Forecast: Braveheart Bio, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$20
−6.01% on the day

The 5 Wall Street analysts covering Braveheart Bio, Inc. hold a median 12-month price target of $47 — +131.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.9B
Ticker Nerd rank
1/ 100
Median analyst target
$47
Analysts covering
5
Revenue$0.0
Operating income−$15.9M
Net income−$15.0M
Free cash flow−$16.9M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
−5.5%
From high
−33.0%
From low
+8.2%
$19
$30
Range since 6 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

BRVE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Braveheart Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
1/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
36
Revisions
26
Value
17
Issuance
13
Momentum
10
Growth
8
Accruals
8
Quality
5
Volatility
3

Size (36): Smaller than most of the companies we track.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BRVE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BRVE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Aug 2026Adjusted close, US dollars
$15$20$25$30$35$40$45$50Sep 26Oct 26Nov 26BRVEHigh $48Median $47Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $40Median $47High $48

The green dot is the last close — the median target sits +131.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Oct 2026Cantor FitzgeraldReiteratesOverweight$40
31 Aug 2026Cantor FitzgeraldInitiatesOverweight$40
31 Aug 2026Goldman SachsInitiatesBuy$48
31 Aug 2026JefferiesInitiatesBuy$48
31 Aug 2026StifelInitiatesBuy$45
31 Aug 2026TD CowenInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BRVE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BRVE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

BRVE vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100Sep 26Oct 26Nov 26BRVES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BRVE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Braveheart Bio, Inc. (BRVE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.0×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
−16.1×

Cheaper than 98% of US stocks

EV / EBITDA
31.3×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
100.3%

Higher than 96% of US stocks

Return on assets
−73.9%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Braveheart Bio, Inc. (BRVE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Braveheart Bio, Inc. has a market value of $1.9B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$29.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$25.2M.

  • Shares outstanding: 73.2M.

  • Trailing P/E: −4.0×; forward P/E: −10.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Braveheart Bio, Inc. employs 49 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Nov 2026

Data provided by Twelve Data

Peers

BRVE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BRVEBraveheart Bio, Inc.$1.9B1
PGENPrecigen, Inc.$1.8B77
GENBGenerate Biomedicines, Inc.$1.8B1
ZBIOZenas BioPharma, Inc.$1.8B20
STOKStoke Therapeutics, Inc.$1.8B43
MAZEMaze Therapeutics, Inc.$1.8B31
SLSSELLAS Life Sciences Group, Inc.$1.8B58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Braveheart Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BRVE news & analysis

Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026

GlobeNewsWire · 30 Oct 2026neutral

Braveheart Bio announced an investor and analyst webinar for November 6, 2026, featuring remarks on its cardiac myosin inhibitor program and the global clinical development of BHB-1893 in obstructive and non-obstructive HCM.

Why it matters — The webinar will provide updates and discussion about the company’s HCM drug-development program.

Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026

GlobeNewsWire · 30 Oct 2026positive

Braveheart Bio announced two upcoming presentations at the AHA Scientific Sessions 2026, including a late-breaking presentation of 52-week extension data for BHB-1893 in obstructive HCM. The meeting will take place November 6–9 in Chicago.

Why it matters — The presentations will provide an update on BHB-1893, a program being developed for obstructive HCM.

Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product

Seeking Alpha · 20 Oct 2026positive

Seeking Alpha describes Braveheart Bio as a late-stage HCM company with two Phase 3 programs funded by $527 million in pro forma cash, supporting operations into 2029 and completion of the LIONHEART-HCM and NOBLEHEART-HCM trials. It highlights Phase 2 findings of rapid, reversible effects with minimal LVEF decline for its non-obstructive HCM molecule.

Why it matters — BRVE watchers may note the reported cash runway, ongoing Phase 3 trials, and Phase 2 safety and clinical-flexibility findings.

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

GlobeNewsWire · 16 Sept 2026neutral

Braveheart Bio announced it will participate in the Stifel Virtual Cardiometabolic Forum on September 30, 2026, where management will take part in a fireside chat at 12:30 p.m. EDT. The company is a clinical-stage biopharmaceutical firm developing therapies for hypertrophic cardiomyopathy and other cardiovascular diseases.

Why it matters — BRVE watchers may be interested as the company's management will gain visibility through a fireside chat at an industry investor forum, potentially increasing awareness of the company's clinical pipeline.

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 8 Sept 2026positive

Braveheart Bio reported unaudited financial results for the second quarter ended June 30, 2026, and announced the initiation of the Phase 3 LIONHEART-HCM trial of BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The company reported cash and cash equivalents of $122.8 million as of June 30, 2026, or $527.3 million after giving effect to its initial public offering, which is expected to support advancement of BHB-1893 through late-stage clinical development.

Why it matters — The Phase 3 trial initiation and substantial post-IPO cash position signal progress in advancing BHB-1893, its lead candidate, toward late-stage development in hypertrophic cardiomyopathy.

FAQ

Frequently asked questions about BRVE stock

What is the BRVE stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Braveheart Bio, Inc. have a median 12-month price target of $47, with estimates ranging from $40 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BRVE stock a buy right now?

Of the 5 analysts covering Braveheart Bio, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Braveheart Bio, Inc. 1 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BRVE?

As at 4 Nov 2026, Braveheart Bio, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (36 of 100).

Will BRVE stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +131.3% from the last close, and Ticker Nerd's factor model ranks Braveheart Bio, Inc. 1 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BRVE stock forecast for 2030?

No analyst covering Braveheart Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRVE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $48 over the next 12 months.

What does Braveheart Bio, Inc. do?

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases.

What is the latest news on BRVE?

The most recent item we track (GlobeNewsWire, 30 Oct 2026): "Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026". Braveheart Bio announced an investor and analyst webinar for November 6, 2026, featuring remarks on its cardiac myosin inhibitor program and the global clinical development of BHB-1893 in obstructive and non-obstructive HCM.

Company

About Braveheart Bio, Inc.

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead program centers on BHB-1893, an oral small-molecule cardiac myosin inhibitor designed for both obstructive and non-obstructive forms of the disease. The company’s work is aimed at advancing treatment options for patients with limited therapeutic choices, with a focus on cardiovascular medicine and heart muscle disorders. Braveheart Bio operates as a drug-development company, supporting research and clinical development across its current pipeline rather than commercial product sales. Headquartered in San Francisco, California, Braveheart Bio was incorporated in 2024 and is positioned within the biotechnology sector as a developer of specialized cardiovascular therapies.

CEO Dr. Travis Murdoch B.S., M.D., M.Sc. · 49 employees · United States · https://www.braveheart.bio